UnitedHealth Group Earnings: Is Obamacare Holding Growth Back?

The stock has pressed to new highs, but will earnings keep up?

Jul 16, 2014 at 5:00PM

Source: Department of Health and Human Services.

On Thursday, UnitedHealth Group (NYSE:UNH) will release its quarterly report, and shareholders are of two minds about the health insurer's recent results. On one hand, the stock has pushed ahead to all-time highs. But increasingly, pressure from WellPoint (NYSE:ANTM), Humana (NYSE:HUM), and other major players in the health-insurance arena is taking its toll on UnitedHealth's profitability, and the fallout from the Affordable Care Act remains a concern for investors going forward.

UnitedHealth Group has been a leader in the health insurance industry for years, with a wide-ranging business that has grown to international scope. Yet more recently, UnitedHealth has failed to show the same promise that WellPoint, Humana, and other competitors have shown, as the rise of Obamacare seems to have leveled the playing field somewhat for industry participants. Investors now want to know how UnitedHealth will reassert its dominance in health insurance. Let's take an early look at what's been happening with UnitedHealth Group over the past quarter and what we're likely to see in its report.

Stats on UnitedHealth Group

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$32.01 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Can UnitedHealth earnings bounce back?
In recent months, investors have grown less enthusiastic about UnitedHealth earnings, cutting their second-quarter estimates by $0.07 per share or about 5%. The stock has kept rising higher, though, with gains of 4% since early April.

UnitedHealth Group's first-quarter results showed the tug-of-war that the health insurance industry is going through right now. The implementation of Obamacare helped send UnitedHealth's Medicaid business soaring, with a 5% jump in overall sales due largely to the Medicaid segment. But a big gain in membership due to a contract from the Tricare program for U.S. military servicemembers was partially offset by a drop of 780,000 members on the commercial side of its business, and net margins were hit by more than a percentage point because of health-care reform, helping to pull earnings down from year-ago levels.


Source: UnitedHealth Group.

To maximize its profit, UnitedHealth has to balance two very different parts of its business. On one hand, areas like its Optum pharmacy benefits and health-care services business have performed extremely well lately, with big jumps in revenue as clients seek more advice on how to keep their health-care costs down and promote wellness and other initiatives that both improve health and reduce expenses. At the same time, though, UnitedHealth and peers WellPoint and Humana rely to a large extent on government programs, and pricing pressure to cut reimbursement rates from Medicare inevitably weigh on profits.

Yet on the execution front, UnitedHealth hasn't performed as well as some of its peers. Increased spending on hepatitis C drug Sovaldi had a substantial impact on earnings, catching UnitedHealth by surprise. By contrast, WellPoint seemed better prepared for hep-C drug spending, giving UnitedHealth insight into an area where it could improve on its track record.

Nevertheless, UnitedHealth has positioned itself for long-term success. Expansion into Brazil has gone well, providing revenue that's independent of U.S. health-care trends. Moreover, now that some of Obamacare's kinks have worked themselves out, UnitedHealth plans to boost its exposure to public health-insurance exchanges in the next year. With efforts to keep its provider network efficient, UnitedHealth also hopes to qualify for bonus payments from the government for its Medicare Advantage programs.

In the UnitedHealth earnings report, watch to see whether the company foresees an end to its earnings headwinds. With so much opportunity from favorable demographics and health-care trends, UnitedHealth can't afford to let WellPoint, Humana, and other players in the insurance industry eat away at its leadership position.

Leaked: This coming blockbuster could make even UnitedHealth Group jealous
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Click here to add UnitedHealth Group to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends UnitedHealth Group and WellPoint. The Motley Fool owns shares of WellPoint. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information